# Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Study · id `cardio:ct-nct03785405` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03785405](<https://clinicaltrials.gov/study/NCT03785405>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03785405

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.

## Technical summary

Registry record NCT03785405. Allocation not applicable; no masking; primary purpose treatment. Start 2019-05-02 (actual); primary completion 2023-12-29 (actual). Results posted on 2024-07-16.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 216 participants (enrolled count; ClinicalTrials.gov record NCT03785405, source copy `cardio:ctgov-nct03785405-2025-05-16`, retrieved 2026-10-26)
- Started: 2019-05-02 (actual) (ClinicalTrials.gov record NCT03785405, source copy `cardio:ctgov-nct03785405-2025-05-16`, retrieved 2026-10-26)
- Primary completion: 2023-12-29 (actual) (ClinicalTrials.gov record NCT03785405, source copy `cardio:ctgov-nct03785405-2025-05-16`, retrieved 2026-10-26)
- Completion: 2023-12-29 (actual) (ClinicalTrials.gov record NCT03785405, source copy `cardio:ctgov-nct03785405-2025-05-16`, retrieved 2026-10-26)
- Results first posted: 2024-07-16 (ClinicalTrials.gov record NCT03785405, source copy `cardio:ctgov-nct03785405-2025-05-16`, retrieved 2026-10-26)
- Countries: United States; Argentina; Austria; Bulgaria; Canada; Croatia; Czechia; Finland; France; Germany; Hungary; India; Israel; Italy; Japan; Lebanon; Poland; Portugal; Russia; Singapore; South Africa; South Korea; Spain; Switzerland; Taiwan; Thailand; Türkiye (ClinicalTrials.gov record NCT03785405, source copy `cardio:ctgov-nct03785405-2025-05-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03785405-2025-05-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
- Condition: Heart Failure
- Intervention (Drug): sacubitril/valsartan
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Sacubitril/valsartan (combination) (`cardio:sacubitril-valsartan`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 84b3b47fe48b7d4b666c777dde4648f348359e9c5695a44cc022f98dfb24c48f
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
